coronary disease

Lo más importante del año en enfermedades coronarias

These Were the Most Relevant Article of 2018 in the Field of Coronary Diseases

1- The CULPRIT-SHOCK Study Is Finally Published in NEJM and It Is Bound to Change Guidelines During SOLACI’s coverage of the TCT 2017 Congress in Denver, Colorado, we already mentioned some of the outcomes of this study that has arrived to revolutionize clinical practice, given the differences between its results and those of the classic...

Coronary Disease in Diabetes: Diabetic Patients Have Much Greater Plaque Progression

Patients with diabetes mellitus experience significantly greater plaque progression, particularly regarding adverse plaque. Male sex and baseline plaque volume >75% were identified as independent risk factors for plaque progression; the latter actually tripled the risk. This study with tomographic follow-up sought to determine the rate and extent of plaque progression, changes in plaque features, and...

La enfermedad coronaria funciona como un predictor a 30 días en el TAVI

Coronary Disease Works as a 30-Day Predictor in TAVR

The association between aortic stenosis and coronary disease is common, since both conditions share pathogenesis, risk factors, and symptoms. Transcatheter aortic valve replacement (TAVR) is currently indicated for high-risk and inoperable patients. It also appears as a valid alternative for the treatment of intermediate-risk patients, and it could soon be indicated for low-risk patients. Coronary...

Severidad de una lesión valorada con FFR

Severity of Lesions Assessed by FFR in Coronary Disease: Is It Associated with Major Events?

In patients with coronary disease, the prognosis depends on the extent and reversibility of myocardial ischemia. Whether the outcome also depends on the severity of stenosis as determined by fractional flow reserve (FFR) has not been studied yet.   This study investigates the relationship between fractional flow reserve values and vessel-related events. Major adverse cardiovascular...

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial infarction. Reducing heart rate with ibravadina inhibitor may confer symptomatic benefit of angina and reduce coronary events in patients with chronic coronary disease and a resting heart rate ≥ 70 bpm....

TACT trial: Chelation Therapy for the Treatment of Coronary Disease.

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol content, and oxidative stress of plates. The placebo-controlled double blind design study included 1708, randomized to EDTA + vitamins, EDTA + placebo, placebo + vitamins o placebo + placebo. Primary end...

Is the 2nd generation DES an alternative to surgery in multivessel coronary disease?

The benefits of 2nd generation drug-eluting stents (DES) are being compared with Coronary artery bypass graft surgery (CABG), looking to achieve a safe, effective, less invasive and as complete as possible revascularization. As background of SYNTAX, the stent thrombosis (ST) with Taxus, reached 25% of the events in the group of intervention (PCI), so that...

Double Anti platelet aggregation would be sufficient for six months after angioplasty in patients with stable coronary disease NSTSEACS.

Original title: 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug. Reference: Eluting Stents in Patients Nonresistant to Aspirin The Randomized, Multicenter ITALIC Trial.  JACC.VOL. 65, NO. 8, 2015 Current recommendations on dual antiplatelet therapy (DAPT) are under review, particularly in acute coronary events due largely to the advent of second-generation stents. This work studied the hypothesis...

Top